Repository logo

Characterizing Cysteine Modifications in Parkinson’s-Linked Parkin and Their Influence on Dopaminergic Cell Health

dc.contributor.authorFehr, Travis
dc.contributor.supervisorSchlossmacher, Michael
dc.date.accessioned2021-01-11T20:19:18Z
dc.date.available2021-01-11T20:19:18Z
dc.date.issued2021-01-11en_US
dc.description.abstractRecessive mutations in PRKN, the gene coding for parkin, cause early-onset Parkinson disease (PD). Neuronal loss in parkin-deficient PD cases is restricted to specific dopamine-producing neuronal populations that have high oxidative stress. Our lab recently uncovered a role for parkin in redox biology, whereby the wild-type protein neutralizes reactive oxygen species (ROS) as well as reactive electrophilic species (RES), including dopamine itself and its metabolites. We propose that this may be an essential function that parkin confers in these vulnerable neurons. In the current work, I have further characterized parkin’s redox function by using mass spectrometry (LC-MS/MS) to analyze the redox state of parkin’s cysteines following exposure to H2O2 by differentially labelling oxidized vs. reduced cysteines; furthermore, I mapped adducts of reactive dopamine metabolites to specific cysteine residues. Using a differential labelling technique followed by LC-MS/MS analysis, we found that the redox state of parkin’s cysteines is altered when exposed to oxidative stress. There, increased oxidation of parkin correlated with both aggregation and insolubility, a phenomenon also observed in adult human brain. Furthermore, by using LC-MS/MS, I have detected adducts of oxidized dopamine metabolites at various cysteine residues on parkin; there, one specific site, the primate-specific residue C95, showed a particular vulnerability to modification by dopamine. This evidence confirmed our previous biochemical assays that had suggested parkin can be directly modified by dopamine. Expanding on previous data generated in our lab, which showed that the presence of wild-type (WT) parkin promotes the formation of melanin in vitro, I created a C95A mutation-carrying, recombinant parkin protein and observed that its ability to promote melanin formation in vitro was abolished. Similarly, we found that p.C95A parkin is not able to protect cells from dopamine-induced ROS stress as well as does WT parkin. Overall, these results suggest that parkin’s ability to neutralize ROS, to sequester reactive dopamine metabolites (RES) and to promote melanin formation, all via its cysteine oxidation, may confer protection of vulnerable dopamine-producing cells in adult human brain.en_US
dc.identifier.urihttp://hdl.handle.net/10393/41643
dc.identifier.urihttp://dx.doi.org/10.20381/ruor-25865
dc.language.isoenen_US
dc.publisherUniversité d'Ottawa / University of Ottawaen_US
dc.subjectParkinen_US
dc.subjectDopamineen_US
dc.subjectCysteineen_US
dc.subjectRedoxen_US
dc.subjectParkinson diseaseen_US
dc.subjectMass spectrometryen_US
dc.titleCharacterizing Cysteine Modifications in Parkinson’s-Linked Parkin and Their Influence on Dopaminergic Cell Healthen_US
dc.typeThesisen_US
thesis.degree.disciplineMédecine / Medicineen_US
thesis.degree.levelMastersen_US
thesis.degree.nameMScen_US
uottawa.departmentMédecine cellulaire et moléculaire / Cellular and Molecular Medicineen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail ImageThumbnail Image
Name:
Fehr_Travis_2021_Thesis.pdf
Size:
3.83 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail ImageThumbnail Image
Name:
license.txt
Size:
6.65 KB
Format:
Item-specific license agreed upon to submission
Description: